TAK News and Press, Takeda Pharmaceutical Company Limited American Depositary Shares From 07/07/23

2023-07-07 14:00:03 ET Summary Shares of diagnostics and drug discovery concern Adaptive Biotechnologies Corporation have crashed over 90% as the commercial-stage concern struggles with profitability. On the top line, the company’s clonoSEQ test volume increased 57% year-ov...

2023-07-01 01:55:50 ET Summary Adapt Biotechnologies comes with interesting core offerings in immune medicine. The firm's MRD segment is driving the bulk of sales upsides, backed by sales volumes of its immunoSEQ and clonoSEQ units. Looking forward, ADPT reiterates its full-ye...

2023-06-25 12:00:43 ET The pharmaceutical industry is caught between a rock and a hard place. If the pricing concerns sparked by the recently enacted Inflation Reduction Act are not enough, the Federal Trade Commission has stepped up scrutiny over merger deals, hurting prospects for a buyou...

Data from First and Only Phase 3 Controlled Trial in cTTP Demonstrate Strong Efficacy and Favorable Safety Profile with TAK-755 (recombinant ADAMTS13), Compared to Plasma-Based Therapies Patients Receiving TAK-755 Achieved an Increase in Plasma ADAMTS13 Enzyme Activity Levels, Which A...

2023-06-21 05:10:17 ET Summary Kamada Ltd. has potential catalysts for growth, capital attraction and regulatory tailwinds. The company's valuation appears attractive, with forward estimates suggesting a possible re-rating. Key risks center around the investment in 2x new manu...

2023-06-21 02:47:25 ET Summary Takeda Pharmaceutical's stock has appreciated 10% since December, with economic and fundamental catalysts supporting a buy rating. TAK has shown strong growth in revenue and operating capital as well as promise in its pipeline and geographic diversif...

Pivotal Phase 3 Findings with HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] Showed a Clinically Significant Reduction in Relapse Rate as well as a Delayed Time to Relapse Compared to Placebo When Used as a Maintenance Therapy in Adult Patients with CIDP ...

— Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer (0.66 HR) — — Data support regulatory submissions in the U.S., Europe and Japan during 2023 ...

− Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer (0.66 HR) − Data support regulatory submissions in the U.S., Europe and Japan during 2023 Takeda ( ...

— Application Includes Data from Phase 3 FRESCO-2 and FRESCO Clinical Trials, which Demonstrated Superiority of Fruquintinib Plus Best Supportive Care (BSC) vs. Placebo plus BSC for Adult Patients with Previously Treated Metastatic Colorectal Cancer Takeda ( TSE:4502/NYSE:TAK...